Moreover, our study confirmed that the inhibition of neurotransmitters (e.g., 5-HT and Tac1) and its receptor (e.g., 5-HT3R and NK-1R), the regulation of intestinal microbiota, the inhibition of inflammation in colon, and the protection of intestinal mucosa barrier via the combination therapy are extremely important to alleviate CINV in CRC mice (Figure 6). The gene discussed is TACR1; the disease is colorectal carcinoma.